SANUWAVE Health Inc

SANUWAVE Health Inc(SNWV)股票分析

$2.210

-0.040 (-1.79%)收盘时

Loading chart…
最高
2.650
开盘
2.340
成交量加权均价
2.32
成交量
361.26K
市值
—
最低
2.105
成交额
838.71K
企业价值/息税折旧摊销前利润(TTM)
-141.67

Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others.

AI 分析 of SANUWAVE Health Inc (SNWV)

卖出

Sanuwave Health, Inc. is not a good buy right now. The current price is $2.21, which is significantly down from its 52-week high of $36.20, reflecting a staggering 92.35% year-to-date decline. Additionally, the RSI is extremely low at 13.769, indicating oversold conditions, but this may not be a strong enough signal to counteract the underlying financial issues. The company has recently faced a 21% decrease in reimbursement rates, which could further pressure revenues. The main risk is the high debt-to-equity ratio of 688.05%, suggesting financial instability.

估值指标

SANUWAVE Health Inc(SNWV)当前预期市盈率为 18.25,5 年平均预期市盈率为 21.60。

预期市盈率

合理
5 年均值 P/E
21.60
当前P/E
18.25
高估
37.29
低估
5.92

预期 EV/EBITDA

严重低估
5 年均值 EV/EBITDA
-5.23
当前EV/EBITDA
-141.67
高估
58.87
低估
-69.32

预期市销率

低估
5 年均值 P/S
2.63
当前P/S
0.30
高估
4.90
低估
0.35

Alphio AI 对 SNWV 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%SNWV

$40.32

情景价格

基

基准

基准 · 50%SNWV

$36.11

情景价格

悲

悲观

悲观 · 25%SNWV

$28.03

情景价格

事件时间线

2026-11-05 (ET)

10:01:00

SANUWAVE Health Inc Trading Resumes

10:00:00

SANUWAVE Health Inc Trading Halted Due to Volatility

2026-07-13 (ET)

17:00:00

Sanuwave Health Q2 Revenue Expected to Reach $9.6M-$9.8M

2026-05-12 (ET)

17:10:00

Sanuwave Health Sees Q2 Revenue of $11.1M-$11.6M

17:10:00

Sanuwave Reports Q1 Revenue of $9.6M

资讯

SNWV 常见问题 —— 由 Alphio AI 解答

Sanuwave Health, Inc. is an ultrasound and shock wave technology company. It is a provider of wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive, and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. It applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, and aesthetic/cosmetic. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression technology to converge at precise selected targets to produce short duration compression burst and are used in both wound and orthopedic applications under the brand names dermaPACE and others. It operates in the Healthcare sector.

Sanuwave Health, Inc. is not a good buy right now. The current price is $2.21, which is significantly down from its 52-week high of $36.20, reflecting a staggering 92.35% year-to-date decline. Additionally, the RSI is extremely low at 13.769, indicating oversold conditions, but this may not be a strong enough signal to counteract the underlying financial issues. The company has recently faced a 21% decrease in reimbursement rates, which could further pressure revenues. The main risk is the high debt-to-equity ratio of 688.05%, suggesting financial instability.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易